7 recruiting, 4 completed, 3 unknown, 2 terminated. 17 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Recruiting 7, Completed 4, Unknown 3, Terminated 2, Active not recruiting 1 |
| Phase 1 | 9 | Recruiting 6, Unknown 2, Active not recruiting 1 |
Follow Tumor, Solid: new trials by email Literature Review of Tumor, Solid trials Research Report on Tumor, Solid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment XNW29016 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 132 | 2025-04-11 | 2026-10-16 |
| AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors AD1208 - Solid Tumor, Adult, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Avelos Therapeutics Inc. | 36 | 2025-03-11 | 2025-04-04 |
| Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan Enray Pharmaceutical Sciences Company | 54 | 2024-11-12 | 2026-02-25 |
| TumorGlow Intraoperative Molecular Imaging (IMI) Indocyanine Green - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | University of Pennsylvania | 500 | 2024-08-14 | 2026-03-09 |
| Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy - Tumor, Solid | Phase 2 | Recruiting | Centre Francois Baclesse | 52 | 2024-03-11 | 2026-07-02 |
| Autologous TLPO Vaccine Basket Tumor lysate, particle only (TLPO) vaccine - Tumor, Solid, Tumor Metastasis | Phase 2 | Terminated | Elios Therapeutics, LLC | 63 | 2023-11-29 | 2025-09-15 |
| LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. LEU011 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Leucid Bio | 17 | 2023-11-13 | 2026-08-31 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents OR502, Cemiplimab - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | OncoResponse, Inc. | 168 | 2023-10-24 | 2025-01-07 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
| Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Ulixertinib, Hydroxychloroquine - Tumor, Solid, Gastrointestinal Cancer | Phase 2 | Terminated | BioMed Valley Discoveries, Inc | 47 | 2022-05-26 | 2025-09-25 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
| [18F]FPIA PET/CT Imaging in Patients With Solid Tumours [18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid), PET/CT - Cancer, Tumor, Solid | Phase 2 | Unknown | University College, London | 21 | 2021-12-07 | 2023-10-03 |
| 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer 68Ga-FAPI-46 PET Scan - Tumor, Solid | Phase 2 | Completed | University Hospital, Essen | 158 | 2021-12-01 | 2024-04-12 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents OR2805, Cemiplimab, Docetaxel - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | OncoResponse, Inc. | 172 | 2021-09-09 | 2023-11-02 |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors BDB001 - Tumor, Solid | Phase 2 | Completed | Eikon Therapeutics | 1 | 2021-08-30 | 2025-11-12 |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies TBX-3400 - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Unknown | Taiga Biotechnologies, Inc. | 60 | 2021-01-25 | 2022-02-02 |
| Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors Durvalumab and Tremelimumab - Tumor, Solid | Phase 2 | Completed | John L. Villano, MD, PhD | 14 | 2019-06-08 | 2025-11-12 |
Neoplasms (17) · Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Colorectal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Thyroid Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Fistula (1) · Gastrointestinal Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Pathological Conditions, Signs and Symptoms (6) · Neoplasms by Site (5) · Neoplastic Processes (5) · Pathologic Processes (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Head and Neck Neoplasms (3) · Lung Neoplasms (3)
cemiplimab (2) · BDB001 (1) · Docetaxel (1) · Hydroxychloroquine (1) · Indocyanine Green (1) · Radiotherapy (1) · Vaccines (1) · durvalumab (1) · lenvatinib (1) · pembrolizumab (1) · tremelimumab (1) · ulixertinib (1)
OncoResponse, Inc. (2) · Aadi Bioscience, Inc. (1) · Avelos Therapeutics Inc. (1) · BioMed Valley Discoveries, Inc (1) · Centre Francois Baclesse (1) · Eikon Therapeutics (1) · Elios Therapeutics, LLC (1) · Evopoint Biosciences Inc. (1) · John L. Villano, MD, PhD (1) · Leucid Bio (1) · Salubris Biotherapeutics Inc (1) · Sichuan Enray Pharmaceutical Sciences Company (1) · Taiga Biotechnologies, Inc. (1) · University College, London (1) · University Hospital, Essen (1)
United States (9) · China (2) · South Korea (2) · United Kingdom (2) · Belgium (1) · France (1) · Germany (1) · Israel (1) · Puerto Rico (1) · Spain (1)
Harry Raftopoulos, MD (1) · John Maher (1) · John Villano, MD (1) · Tara Barwick (1)
PMID 38331453, PMID 38782454, PMID 39443386, PMID 40774265, PMID 42637259